. 2020 Nov 17;184(2):267–276. doi: 10.1530/EJE-20-0325
This work is licensed under a Table 1.
Treatment-naïve/prepubertal (NPP) patient characteristics at baseline in patients with or without LS (Enrolled population).
| Characteristics | NPP-LS (n = 21) | NPP-non-LS (n = 117) | P valuea | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| nb | n (%) | Mean (s.d.) | 95% CI | Median (Q1; Q3) | nb | n (%) | Mean (s.d.) | 95% CI | Median (Q1; Q3) | ||
| Females | 21 | 9 (42.9) | 24.5; 63.5 | 117 | 46 (39.3) | 30.9; 48.4 | 0.76c | ||||
| Age at first injection, years | 21 | 6.07 (3.49) | 4.49; 7.66 | 6.11 (2.82; 8.30) | 117 | 8.44 (3.45) | 7.81; 9.07 | 8.23 (5.70; 11.21) | 0.006f | ||
| Height, SDS | 16 | −5.62 (1.95) | −6.66; −4.58 | −5.88 (−6.89; −4.22) | 109 | −3.46 (1.05) | −3.66; −3.26 | −3.26 (−3.82; −2.88) | <0.001f | ||
| Height velocity, cm/year | 7 | 5.67 (1.10) | 4.66; 6.69 | 5.64 (5.12; 6.24) | 63 | 4.74 (1.77) | 4.29; 5.19 | 4.91 (3.95; 5.71) | 0.174f | ||
| Weight, SDS | 17 | −4.63 (1.35) | −5.32; −3.93 | −4.61 (−5.44; −3.83) | 110 | −3.04 (1.12) | −3.26; −2.83 | −3.07 (−3.57; −2.32) | <0.001f | ||
| BMI, SDS | 16 | −0.24 (1.30) | −0.94; 0.45 | −0.19 (−0.92; 0.29) | 98 | −0.80 (1.34) | −1.07; −0.53 | −0.76 (−1.70; 0.02) | 0.126e | ||
| Mother’s height, cm | 18 | 156.0 (7.4) | 152.3; 159.7 | 155.3 (151.9; 160.0) | 108 | 157.8 (7.2) | 156.4; 159.2 | 158.0 (153.0; 162.7) | – | ||
| Father’s height, cm | 18 | 168.5 (7.6) | 164.7; 172.3 | 169.2 (164.5; 174.8) | 107 | 172.6 (8.1) | 171.0; 174.1 | 172.0 (168.0; 178.0) | – | ||
| IGF1, ng/mL | 9 | 39.37 (16.25) | 26.89; 51.86 | 37.00 (25.00; 38.93) | 103 | 88.30 (67.89) | 75.04; 101.57 | 70.5 (39.00; 119.00) | 0.007f | ||
| Peak stimulated GH level, ng/mL | 13 | 35.50 (20.53) | 23.10; 47.91 | 33.30 (25.00; 38.3) | 84 | 24.61 (24.87) | 19.22; 30.01 | 15.10 (11.25; 26.10) | 0.014f | ||
| Primary diagnosis: SPIGFD† | 21 | 21 (100) | 84.5; 100.0 | 117 | 106 (90.6) | 83.9; 94.7 | – | ||||
| History of hypoglycaemia | 21 | 4 (19.0) | 7.7; 40.0 | 117 | 3 (2.6) | 0.9; 7.3 | 0.011d | ||||
†Including LS, as reported by the investigator; aNPP-non-LS vs NPP-LS; bnumber of patients with available data; cChi-square test; dFisher’s test; eANOVA; fWilcoxon test.
BMI, body mass index; GH, growth hormone; IGF1; insulin-like growth factor-1; SDS, standard deviation score; SPIGFD, severe primary IGF1 deficiency.